FIELD: veterinary science.
SUBSTANCE: a dog should be introduced with 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazole-1-il]benzene sulfonamide or its pharmaceutically acceptable salt at daily dosage ranged about 0.1-10 mg/kg body weight.
EFFECT: higher efficiency of therapy.
4 cl,262 ex, 12 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZOLYL-SUBSTITUTED BENZENESULFONEAMIDE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF TREATMENT OF PATIENTS WITH INFLAMMATION OR INFLAMMATION-ASSOCIATED DISEASES | 1994 |
|
RU2139281C1 |
| METHOD FOR APPLYING CYCLOOXYGENASE-2 INHIBITOR FOR TREATMENT AND PROPHYLAXIS OF NEOPLASIA | 1997 |
|
RU2239429C2 |
| 2-CYCLOOXYGENASE INHIBITORS AS ANTIANGIOGENIC AGENTS | 1997 |
|
RU2268716C2 |
| SUBSTITUTED ISOXAZOLES, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD OF INFLAMMATION SUPPRESSION | 1996 |
|
RU2200158C2 |
| METHOD OF PREPARING 3-HALOGENALKYL-1H- PYRAZOLES | 1996 |
|
RU2169143C2 |
| DIKETONE AS INTERMEDIATE FOR 3-HALOGENE-1H-PYRASOLES | 1996 |
|
RU2251543C2 |
| PHARMACEUTICAL COMPOSITION FOR USING IN THERAPY OF MALIGNANT NEOPLASM COMPRISING COMBINATION OF BISPHOSPHONATE, COX-2 INHIBITOR AND TAXOL | 2002 |
|
RU2317819C2 |
| DERIVATIVES OF PYRAZOLINE, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION | 1999 |
|
RU2233272C2 |
| 3-(5)-HETEROARYL-SUBSTITUTED PYRAZOLES AS KINASE P38 INHIBITORS | 1998 |
|
RU2249591C2 |
| 1-(4-ISOXAZOLE-5-YL)-1H-PYRAZOLE-1-YL)-2-METHYLPROPANE-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | 2018 |
|
RU2785342C2 |
